Adult patients with psoriasis now have a new drug option in the SUS, risanquizumab. The medication is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, according to the Clinical Protocol and Therapeutic Guidelines of the disease.
The incorporation of the drug in the SUS was published on Monday (21), in the Official Gazette (DOU). The Ministry of Health has up to 180 days to offer the drug for the treatment of the disease in SUS after the date of publication.
Psoriasis is a chronic, non-contagious skin disease, characterized by reddish or pinkish plaques, covered by whitish scales, which affects the skin, nails and can affect the joints. The disease can occur at any age, both in men and women and, so far, has no cure.
Currently, the treatment of psoriasis in SUS aims to help patients achieve prolonged periods of remission of the disease. Phototherapy and photosensitization phototherapy treatments are offered, as well as medications such as cyclosporine (capsules or oral solution), methotrexate (tablet or injection), acitretin (capsules), calcipotriol (ointment), clobetasol (cream) and dexamethasone (cream). These drugs, in addition to medical treatments and phototherapy sessions, improve the lesions, but do not cure the disease. The best form of treatment and administration of medicines is based on clinical evaluation, case by case, between the doctor and the patient.